Zobrazeno 1 - 10
of 51
pro vyhledávání: '"35"'
Autor:
John G. Kuhn, Virginia G. Kaklamani, Joe Ensor, Anna Belcheva, Kartik Anand, Luz A. Venta, Nakul Gupta, Yitian Xu, Ping-Ying Pan, Mary R. Schwartz, Andrew W. Chung, Tejal Patel, Shu-Hsia Chen, Angel Rodriguez, Jorge Darcourt, Polly A. Niravath, Nabeel Attarwala, Qiuying Chen, Eric H. Bernicker, Licheng Zhang, Wei Qian, Jenny C. Chang
Publikováno v:
Cancer Research. 81:CT175-CT175
Targeting inducible nitric oxide in a first-in-class phase 1/2 trial in triple-negative breast cancer patients diminishes M2 macrophage polarization and led to a robust clinical response. Andrew W. Chung*, Kartik Anand*, Polly Niravath* (co-first aut
Autor:
Natacha Duquette, Alain Zgheib, Jean-Christophe Currie, Alain Larocque, Michel Demeule, Cyndia Charfi, Christian Marsolais, Richard Béliveau, Borhane Annabi
Publikováno v:
Cancer Research. 80:2910-2910
Rational: Breast cancers are comprised of several subtypes that share similar clinicopathological features, but that also exhibit several different biological characteristics. Triple-negative breast cancer (TNBC), which comprises 10-20% of breast can
Autor:
Maureen E. Trudeau, L.B. Pritzker, Baoqing Guo, Amadeo M. Parissenti, X. Wang, Mu Zhu, Kenneth P.H. Pritzker
Publikováno v:
Cancer Research. 73:P1-08
Background: We recently reported that epirubicin/docetaxel treatment of locally advanced breast cancer patients in the MA.22 clinical trial reduced tumor RNA integrity and that low mid-treatment tumor RNA integrity was associated with a pathologic co
Publikováno v:
Cancer Research. 71:P5-19
Background Parenteral taxanes (docetaxel, paclitaxel) are among the most active agents in treating metastatic breast cancer (MBC). However, their use is limited by inherent or acquired multidrug resistance, hypersensitivity, and neurotoxicity. Teseta
Autor:
Shibu Thomas, Ryan P. McMullin, Daniel Sondheim, Gormley Michael, Deborah Ricci, Corey Eva, Lisha G. Brown, Holly M. Nguyen, Yashoda Rajpurohit, Himanshu Gupta
Publikováno v:
Cancer Research. 76:3074-3074
Results from clinical and preclinical investigations suggest potential survival benefits from more aggressive early treatment of some patients. Our objective was to evaluate in vivo the efficacy of adding docetaxel (DOC) or ARN509, alone or in combin
Autor:
Prabhjot Mundi, Katherine D. Crew, Eileen P. Connolly, Dawn L. Hershman, Kevin Kalinsky, Matthew Maurer, Andrea Calfiano, Hanina Hibshoosh
Publikováno v:
Cancer Research. 75:OT1-1
Background: Neoadjuvant chemotherapy (NACT) is standard of care in operable breast cancer (BC). There are no therapies that have demonstrated benefit in patients who failed to achieve a pathologic complete response (pCR). There remains an unmet need
Autor:
S-A Im, Hua Li, Paul A. Moore, Y-J. Bang, Jeffrey L. Nordstrom, Giuseppe Giaccone, D-Y. Oh, Edwin P. Rock, Todd M. Bauer, Jan Baughman, Shengyan Hong, H. A. Burris
Publikováno v:
Cancer Research. 79:P6-18
Background Margetuximab is an Fc-optimized anti-HER2 antibody that recognizes the same epitope as trastuzumab. Margetuximab has increased affinity for the activating CD16A Fc-receptor on NK cells and macrophages as well as decreased affinity for the
Autor:
Martin Alessandro Sanchez, Ida Paris, Stefano Magno, Gianluca Franceschini, Giovanni Scambia, Gabriella Ferrandina, D. Terribile, Luisa Carbognin, Riccardo Masetti, D Di Giorgio, Cristina Accetta, A Fulvi, T Pasciuto
Publikováno v:
Cancer Research. 79:P1-11
Background. Alopecia (A) is a common and emotionally traumatic adverse effect for breast cancer (BC) patients (pts) undergoing chemotherapy (CT). Food and Drug Administration (FDA) cleared the DigniCap® SCD, for patients with breast cancer in 2015.
Autor:
D. Serin, L. Roca, Patrice Viens, A. Vindevoghel, A. Monnier, Henri Roché, Bruno Audhuy, Hugues Bourgeois, E. Brain, C. Dopchie, D. Allouache, N. Dohollou, J-M Ferrero, L. Mauriac, M. Spielmann, Gilles Romieu, M. Jimenez, J-L Canon, L. Cany, Elisabeth Luporsi
Publikováno v:
Cancer Research. 69:602-602
Objective: To evaluate the combined administration of Docetaxel (D) and Epirubicin (E) versus FEC 100 on 5-year disease-free survival (DFS) among non metastatic lymph node-positive breast cancer patients (pts).Patients and Methods: Main inclusion cri
Autor:
Masahiro Kashiwaba, Yoshinori Hasegawa, Toshinari Yamashita, M. Toi, Kazutaka Narui, T Kawasoe, Masahiro Kitada, Rikiya Nakamura, Noriyuki Masuda, Nobuki Matsunami, Tetsuhiro Yoshinami, Hiroko Bando, K Yanagihara, Hiroshi Yano, Satoshi Morita, Masaya Hattori, Hidetoshi Kawaguchi, Takeshi Nagashima, Shinji Ohno
Publikováno v:
Cancer Research. 78:P5-21
Background: Pertuzumab provided overall and progression-free survival (PFS) benefits in HER2-positive metastatic breast cancer patients (pts) in the CLEOPATRA (Clinical evaluation of docetaxel, pertuzumab and trastuzumab) study. However, few studies